BRCA1 and prostate carcinoma: Lucaparib maintenance therapy is an excellent treatment for patients with platinum-sensitive advanced pancreatic cancer with BRCA1/2 or PALB2 pathogenic variants, primarily in ovarian and prostate cancers.